3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow PankoMab-GEX: new trials by email Literature Review of PankoMab-GEX trials Research Report on PankoMab-GEX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab) - Solid Tumor, Adult | Phase 1 | Completed | Glycotope GmbH | 50 | 2017-11-02 | 2021-07-12 |
| PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer PankoMab-GEX, Placebo - Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer | Phase 2 | Completed | Glycotope GmbH | 216 | 2013-09-01 | 2020-10-22 |
| PankoMab-GEX™: Phase 1 Dose Escalation Study PankoMab-GEX™ - Solid Tumors | Phase 1 | Completed | Glycotope GmbH | 74 | 2009-11-01 | 2021-05-20 |
Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Glycotope GmbH (3)
Germany (3) · Italy (3) · Spain (2) · Hungary (1) · Poland (1) · Romania (1) · Russia (1) · Switzerland (1) · United Kingdom (1)
Jonathan Ledermann, MD (1) · Sebastian Ochsenreither, Dr. med. (1)
PMID 27285281, PMID 34920291, PMID 35397434
2017 (1)